Laquinimod   Gehört zu der Substanzgruppe der Chinoline, die früher gegen Malaria eingesetzt wurden. Laquinimod ist die Nachfolgesubstanz von Linomid und soll entzündungshemmende Wirkung auf das Immunsystem haben.   9. 12. 2010; HANDELSZEITUNG, Teva Pharmaceutical kommt mit Multiple-Sklerose-Tablette Laquinimod voran http://www.handelszeitung.ch/artikel/Management-AWP_Teva-Pharmaceutical-kommt-mit-Multiple-Sklerose-Tablette- Laquinimod-voran_825990.html   16. 12. 2010; PubMed.gov; Oral laquinimod treatment in multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/21163185 „CONCLUSIONS: Laquinimod is a novel, orally administered immunomodulator that has advanced to phase III study, a pre- submission stage to the regulatory agencies, and may become an alternative to the current injectable first-line treatments for RRMS.“   10. 2. 2011; PubMed.gov;  Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/21306281   6. 8. 2013; PubMed.goc; Laquinimod for multiple sclerosis. http://www.ncbi.nlm.nih.gov/pubmed/23922214 „AUTHORS' CONCLUSIONS: We found low-level evidence for the use of laquinimod as a disease-modifying therapy for MS because only one study with limited quality (high risk of attrition bias) was included. The published study suggests that laquinimod at a dose of 0.6 mg orally administered once daily may be safe and have potential benefits for most patients with RRMS in the short term. We are waiting for the publication of ongoing trials.“ 27. 1. 2014; DMSG; Laquinimod zur Behandlung der Multiplen Sklerose: Zulassung erst einmal abgelehnt http://www.dmsg.de/multiple-sklerose-news/index.php?w3pid=news&kategorie=therapien&anr=4968 28. 1. 2014; amsel.de; EMA: Zulassung von Laquinimod nicht empfohlen http://www.amsel.de/multiple-sklerose-news/medizin/EMA-Zulassung-von-Laquinimod-nicht-empfohlen_5070 “It’s hard to be a hard man.”   Zur Medikamenten-Übersicht http://georgieff.at/